Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44376   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    152 result(s) found for: pancreatic cancer. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2016-005147-17 Sponsor Protocol Number: AIO-PAK-0216 Start Date*: 2018-01-30
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy
    Medical condition: locally advanced or metastatic pancreatic cancer after failure of a gemcitabine/nab-paclitaxel 1st-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003528-19 Sponsor Protocol Number: Start Date*: 2013-04-16
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial
    Full Title: STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL PANCREATIC CANCER PERSISTING AFTER SURGICAL EXCISION
    Medical condition: pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001119-11 Sponsor Protocol Number: ParvOryx02 Start Date*: 2015-10-15
    Sponsor Name:Oryx GmbH & Co KG
    Full Title: A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer
    Medical condition: Pancreatic Cancer with at least one hepatic metastasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004236-40 Sponsor Protocol Number: I1-GOA-1 Start Date*: 2007-12-10
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer
    Medical condition: advanced metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005168-94 Sponsor Protocol Number: KKS-77-05 Start Date*: 2006-06-20
    Sponsor Name:Philipps-University of Marburg
    Full Title: Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer
    Medical condition: The aim is to evaluate the feasibility of the combined treatment of cetuximab and gemcitabine in patients with R0-resectable pancreatic cancer and to evaluate if the progression free survival can b...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003855-11 Sponsor Protocol Number: 025/05 Start Date*: Information not available in EudraCT
    Sponsor Name:Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze
    Full Title: Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Ge...
    Medical condition: Combination of standard chemotherapy with Gemcitabine and Cisplatin and regional hyperthermia in patients with locally advanced or metastatic pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2008-003993-16 Sponsor Protocol Number: IM-T-hPAM4-02 Start Date*: 2009-04-03
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer
    Medical condition: This is a phase Ib, open-label, dose exploration study of 90-Y-hPAM4 administered as one or more treatment cycles of fractionated radioimmunotherapy in combination with radiosensitizing gemcitabine...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009928-37 Sponsor Protocol Number: CONKO-008 Start Date*: 2009-10-21
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie
    Medical condition: Pancreatic cancer patients who failed first line therapy with gemcitabine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003657-15 Sponsor Protocol Number: SNOXA12C601 Start Date*: 2017-03-09
    Sponsor Name:NOXXON Pharma AG
    Full Title: A Two-Part, Open-Label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy i...
    Medical condition: Colorectal cancer with liver metastases Pancreatic cancer with liver metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004063-77 Sponsor Protocol Number: ACCEPT Start Date*: 2013-01-17
    Sponsor Name:Klinikum der Universität München, Anstalt des öffentlichen Rechts
    Full Title: Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial
    Medical condition: histologically confirmed diagnosis of metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014476-21 Sponsor Protocol Number: CONKO-007 Start Date*: 2013-02-22
    Sponsor Name:Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. med. Markus F. Neurath
    Full Title: Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial: Chemoradiation following induction chemotherapy compared with chemo...
    Medical condition: Locally advanced non resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005022-71 Sponsor Protocol Number: C-II-004 Start Date*: 2008-01-17
    Sponsor Name:CESAR Central European Society for Anticancer Drug Research – EWIV
    Full Title: Prospective randomized Phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer
    Medical condition: metastatic or locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004086-24 Sponsor Protocol Number: AIO-PAK-0114 Start Date*: 2015-11-18
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel...
    Medical condition: metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001358-29 Sponsor Protocol Number: ARQ 501-212 Start Date*: 2006-10-30
    Sponsor Name:ARQule Inc.
    Full Title: A Phase 2 Study of ARQ 501 in Combination with Gemcitabine in Adult Patients with Treatment Naive, Unresectable Pancreatic Adenocarcinoma
    Medical condition: Treatment naive, unresectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033611 Pancreatic carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001625-40 Sponsor Protocol Number: AX-CL-PANC-PI-008619 Start Date*: 2019-10-21
    Sponsor Name:GWT-TUD GmbH
    Full Title: A MULTICENTER, PHASE I/II STUDY OF SEQUENTIAL EPIGENETIC AND IMMUNE TARGETING IN COMBINATION WITH NAB-PACLITAXEL/GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA
    Medical condition: Pancreatic Ductal Adenocarcinoma (PDAC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    21.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003496-54 Sponsor Protocol Number: FOOTPATH Start Date*: 2019-01-16
    Sponsor Name:University Hospital, LMU Munich (Germany)
    Full Title: A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH)
    Medical condition: Histologically (not cytologically) confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC) [Stage IV according to UICC TNM edition 8 of 201622: each T, each N, M1]
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001609-81 Sponsor Protocol Number: PH-L19ILGEM-01/07 Start Date*: 2007-11-05
    Sponsor Name:Philogen S.pA.
    Full Title: Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer
    Medical condition: Histologically or cytologically confirmed solid cancer of any pathology or adenocarcinoma of the pancreas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065147 Malignant solid tumor LLT
    9.1 10052747 Adenocarcinoma pancreas LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003403-39 Sponsor Protocol Number: CRAD001C2491 Start Date*: 2007-03-29
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer – a dose finding study
    Medical condition: advanced and/or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005471-17 Sponsor Protocol Number: RASH Start Date*: 2012-05-08
    Sponsor Name:Klinikum der Universität München-Großhadern
    Full Title: Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors
    Medical condition: metastatic pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004429-26 Sponsor Protocol Number: Atu027-I-02 Start Date*: 2013-02-25
    Sponsor Name:Silence Therapeutics GmbH
    Full Title: A Phase Ib/IIa study of combination therapy with Gemcitabine and Atu027 in subjects with locally advanced or metastatic pancreatic adenocarcinoma
    Medical condition: Locally advanced or metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    17.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jan 27 05:39:05 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA